Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients

BACKGROUND: In randomized trials (SHARP [Study of Heart and Renal Protection], IMPROVE‐IT [Improved Reduction of Outcomes: Vytorin Efficacy International Trial]), combination of statin and ezetimibe resulted in additional reduction of cardiovascular events. The reduction was greater in patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Ahmed, Osman, Littmann, Karin, Gustafsson, Ulf, Pramfalk, Camilla, Öörni, Katariina, Larsson, Lilian, Minniti, Mirko E., Sahlin, Staffan, Camejo, German, Parini, Paolo, Eriksson, Mats
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405603/
https://www.ncbi.nlm.nih.gov/pubmed/30561264
http://dx.doi.org/10.1161/JAHA.118.009876
_version_ 1783401110918135808
author Ahmed, Osman
Littmann, Karin
Gustafsson, Ulf
Pramfalk, Camilla
Öörni, Katariina
Larsson, Lilian
Minniti, Mirko E.
Sahlin, Staffan
Camejo, German
Parini, Paolo
Eriksson, Mats
author_facet Ahmed, Osman
Littmann, Karin
Gustafsson, Ulf
Pramfalk, Camilla
Öörni, Katariina
Larsson, Lilian
Minniti, Mirko E.
Sahlin, Staffan
Camejo, German
Parini, Paolo
Eriksson, Mats
author_sort Ahmed, Osman
collection PubMed
description BACKGROUND: In randomized trials (SHARP [Study of Heart and Renal Protection], IMPROVE‐IT [Improved Reduction of Outcomes: Vytorin Efficacy International Trial]), combination of statin and ezetimibe resulted in additional reduction of cardiovascular events. The reduction was greater in patients with type 2 diabetes mellitus (T2DM), where elevated remnant cholesterol and high cardiovascular disease risk is characteristic. To evaluate possible causes behind these results, 40 patients eligible for cholecystectomy, randomized to simvastatin, ezetimibe, combined treatment (simvastatin+ezetimibe), or placebo treatment during 4 weeks before surgery, were studied. METHODS AND RESULTS: Fasting blood samples were taken before treatment start and at the end (just before surgery). Bile samples and liver biopsies were collected during surgery. Hepatic gene expression levels were assessed with qPCR. Lipoprotein, apolipoprotein levels, and content of cholesterol, cholesteryl ester, and triglycerides were measured after lipoprotein fractionation. Lipoprotein subclasses were analyzed by nuclear magnetic resonance. Apolipoprotein affinity for human arterial proteoglycans (PG) was measured. Biomarkers of cholesterol biosynthesis and intestinal absorption and bile lipid composition were analyzed using mass spectrometry. Combined treatment caused a statistically significant decrease in plasma remnant particles and apolipoprotein B (ApoB)/lipoprotein content of cholesterol, cholesteryl esters, and triglycerides. All treatments reduced ApoB‐lipoprotein PG binding. Simvastatin and combined treatment modified the composition of lipoproteins. Changes in biomarkers of cholesterol synthesis and absorption and bile acid synthesis were as expected. No adverse events were found. CONCLUSIONS: Combined treatment caused atheroprotective changes on ApoB‐lipoproteins, remnant particles, bile components, and in ApoB‐lipoprotein affinity for arterial PG. These effects might explain the decrease of cardiovascular events seen in the SHARP and IMPROVE‐IT trials. CLINICAL TRIAL REGISTRATION: URL: www.clinicaltrialsregister.eu. Unique identifier: 2006‐004839‐30).
format Online
Article
Text
id pubmed-6405603
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-64056032019-03-19 Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients Ahmed, Osman Littmann, Karin Gustafsson, Ulf Pramfalk, Camilla Öörni, Katariina Larsson, Lilian Minniti, Mirko E. Sahlin, Staffan Camejo, German Parini, Paolo Eriksson, Mats J Am Heart Assoc Original Research BACKGROUND: In randomized trials (SHARP [Study of Heart and Renal Protection], IMPROVE‐IT [Improved Reduction of Outcomes: Vytorin Efficacy International Trial]), combination of statin and ezetimibe resulted in additional reduction of cardiovascular events. The reduction was greater in patients with type 2 diabetes mellitus (T2DM), where elevated remnant cholesterol and high cardiovascular disease risk is characteristic. To evaluate possible causes behind these results, 40 patients eligible for cholecystectomy, randomized to simvastatin, ezetimibe, combined treatment (simvastatin+ezetimibe), or placebo treatment during 4 weeks before surgery, were studied. METHODS AND RESULTS: Fasting blood samples were taken before treatment start and at the end (just before surgery). Bile samples and liver biopsies were collected during surgery. Hepatic gene expression levels were assessed with qPCR. Lipoprotein, apolipoprotein levels, and content of cholesterol, cholesteryl ester, and triglycerides were measured after lipoprotein fractionation. Lipoprotein subclasses were analyzed by nuclear magnetic resonance. Apolipoprotein affinity for human arterial proteoglycans (PG) was measured. Biomarkers of cholesterol biosynthesis and intestinal absorption and bile lipid composition were analyzed using mass spectrometry. Combined treatment caused a statistically significant decrease in plasma remnant particles and apolipoprotein B (ApoB)/lipoprotein content of cholesterol, cholesteryl esters, and triglycerides. All treatments reduced ApoB‐lipoprotein PG binding. Simvastatin and combined treatment modified the composition of lipoproteins. Changes in biomarkers of cholesterol synthesis and absorption and bile acid synthesis were as expected. No adverse events were found. CONCLUSIONS: Combined treatment caused atheroprotective changes on ApoB‐lipoproteins, remnant particles, bile components, and in ApoB‐lipoprotein affinity for arterial PG. These effects might explain the decrease of cardiovascular events seen in the SHARP and IMPROVE‐IT trials. CLINICAL TRIAL REGISTRATION: URL: www.clinicaltrialsregister.eu. Unique identifier: 2006‐004839‐30). John Wiley and Sons Inc. 2018-12-07 /pmc/articles/PMC6405603/ /pubmed/30561264 http://dx.doi.org/10.1161/JAHA.118.009876 Text en © 2018 The Authors. Published on behalf of the American Heart Association, Inc., by Wiley. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc-nd/4.0/ License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non‐commercial and no modifications or adaptations are made.
spellingShingle Original Research
Ahmed, Osman
Littmann, Karin
Gustafsson, Ulf
Pramfalk, Camilla
Öörni, Katariina
Larsson, Lilian
Minniti, Mirko E.
Sahlin, Staffan
Camejo, German
Parini, Paolo
Eriksson, Mats
Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients
title Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients
title_full Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients
title_fullStr Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients
title_full_unstemmed Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients
title_short Ezetimibe in Combination With Simvastatin Reduces Remnant Cholesterol Without Affecting Biliary Lipid Concentrations in Gallstone Patients
title_sort ezetimibe in combination with simvastatin reduces remnant cholesterol without affecting biliary lipid concentrations in gallstone patients
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6405603/
https://www.ncbi.nlm.nih.gov/pubmed/30561264
http://dx.doi.org/10.1161/JAHA.118.009876
work_keys_str_mv AT ahmedosman ezetimibeincombinationwithsimvastatinreducesremnantcholesterolwithoutaffectingbiliarylipidconcentrationsingallstonepatients
AT littmannkarin ezetimibeincombinationwithsimvastatinreducesremnantcholesterolwithoutaffectingbiliarylipidconcentrationsingallstonepatients
AT gustafssonulf ezetimibeincombinationwithsimvastatinreducesremnantcholesterolwithoutaffectingbiliarylipidconcentrationsingallstonepatients
AT pramfalkcamilla ezetimibeincombinationwithsimvastatinreducesremnantcholesterolwithoutaffectingbiliarylipidconcentrationsingallstonepatients
AT oornikatariina ezetimibeincombinationwithsimvastatinreducesremnantcholesterolwithoutaffectingbiliarylipidconcentrationsingallstonepatients
AT larssonlilian ezetimibeincombinationwithsimvastatinreducesremnantcholesterolwithoutaffectingbiliarylipidconcentrationsingallstonepatients
AT minnitimirkoe ezetimibeincombinationwithsimvastatinreducesremnantcholesterolwithoutaffectingbiliarylipidconcentrationsingallstonepatients
AT sahlinstaffan ezetimibeincombinationwithsimvastatinreducesremnantcholesterolwithoutaffectingbiliarylipidconcentrationsingallstonepatients
AT camejogerman ezetimibeincombinationwithsimvastatinreducesremnantcholesterolwithoutaffectingbiliarylipidconcentrationsingallstonepatients
AT parinipaolo ezetimibeincombinationwithsimvastatinreducesremnantcholesterolwithoutaffectingbiliarylipidconcentrationsingallstonepatients
AT erikssonmats ezetimibeincombinationwithsimvastatinreducesremnantcholesterolwithoutaffectingbiliarylipidconcentrationsingallstonepatients